Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Latanoprost/Dor-Tim vs Atoprost in Glaucoma
NCT06369077Phase 4Terminated
- Sponsor
- Connecticut Glaucoma Consultants
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of timolol + brimonidine + dorzolamide + bimatoprost in Open-angle glaucoma (OAG), sponsored by Connecticut Glaucoma Consultants. Started Apr 2024; status: terminated.
02
Drugs
timolol + brimonidine + dorzolamide + bimatoprost
03
Conditions
Open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT06369077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369077.